<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>This article emphasizes the central role of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>-based testing for microsatellite instability followed by performance of genetic counselor-driven germline mutation testing in <z:e sem="disease" ids="C1333990" disease_type="Neoplastic Process" abbrv="">hereditary nonpolyposis colorectal cancer</z:e> (HNPCC) </plain></SENT>
<SENT sid="1" pm="."><plain>Suitably aggressive colorectal <z:hpo ids='HP_0002664'>neoplasm</z:hpo> surveillance is shown to be critical </plain></SENT>
<SENT sid="2" pm="."><plain>Limitations of the evidentiary base for extracolonic screening are conceded, with some cautious suggestions for possible strategies notwithstanding the lack of data </plain></SENT>
<SENT sid="3" pm="."><plain>Advances in chemoprevention have been made in both <z:e sem="disease" ids="C0032580" disease_type="Neoplastic Process" abbrv="">familial adenomatous polyposis</z:e> (clinical trial data favoring eicosapentaenoic acid) and HNPCC (controversial aspirin data) </plain></SENT>
<SENT sid="4" pm="."><plain>For various reasons, however, no agent or combination of agents has yet come into routine use in either condition, with further trials underway or being designed for both conditions </plain></SENT>
</text></document>